Roche (VTX:ROG) received a CHF 260 target price from analysts at Morgan Stanley in a report issued on Friday. The firm presently has a “neutral” rating on the healthcare company’s stock. Morgan Stanley’s target price indicates a potential upside of 4.80% from the company’s previous close.

Other equities analysts also recently issued research reports about the stock. Barclays set a CHF 295 price objective on shares of Roche and gave the stock a “buy” rating in a research note on Wednesday, September 13th. Goldman Sachs Group set a CHF 335 price objective on shares of Roche and gave the stock a “buy” rating in a research note on Thursday, August 24th. Berenberg Bank set a CHF 273 price objective on shares of Roche and gave the stock a “buy” rating in a research note on Tuesday, August 15th. Credit Suisse Group set a CHF 300 price objective on shares of Roche and gave the stock a “buy” rating in a research note on Monday, September 11th. Finally, J P Morgan Chase & Co reissued a “buy” rating on shares of Roche in a research note on Monday, September 11th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of CHF 260.56.

Shares of Roche (VTX:ROG) opened at CHF 248.10 on Friday. Roche has a 12 month low of CHF 218.30 and a 12 month high of CHF 273.

ILLEGAL ACTIVITY NOTICE: “Roche (ROG) PT Set at CHF 260 by Morgan Stanley” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.thecerbatgem.com/2017/12/03/roche-rog-pt-set-at-chf-260-by-morgan-stanley.html.

About Roche

Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

Analyst Recommendations for Roche (VTX:ROG)

Receive News & Stock Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related stocks with our FREE daily email newsletter.